



## Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement

October 23, 2023

*Beverly Hills Cancer Center is the first of up to four prestigious clinical sites expected to evaluate Deltacel™ (KB-GDT-01) in patients with non-small cell lung cancer*

HOUSTON--(BUSINESS WIRE)--Oct. 23, 2023-- **Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”)**, a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study. Pursuant to the agreement, BHCC, one of Southern California’s esteemed private cancer centers, is anticipated to serve as the inaugural clinical site for the evaluation of Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).

The collaboration between Kiromic BioPharma and BHCC underscores the shared commitment between the two organizations to advance the fight against cancer through innovative therapeutic approaches. BHCC is a private, comprehensive facility which includes a radiation oncology center, an infusion center, a full-service diagnostic imaging center (featuring MRI, CT, PET/CT), and a diagnostic laboratory, and has a distinguished history of conducting clinical trials across multiple cancer types.

“As our clinical research program embarks on this groundbreaking clinical journey, we envision a future where patients have access to pioneering therapies and renewed hope in their battle against cancer. For years, BHCC has remained at the forefront of medical excellence, continually seeking innovative approaches to redefine the future of cancer treatment. We are very excited about this collaboration with Kiromic, a very forward-thinking and innovative company, and about this new therapeutic approach and the potential to contribute to science with the ultimate goal of improving the lives of cancer patients worldwide,” said Afshin Eli Gabayan, MD, Medical Director and Principal Investigator at Beverly Hills Cancer Center and Assistant Clinical Professor at UCLA-David Geffen School of Medicine.

“The clinical trial agreement is a momentous first step in the development of this important treatment. BHCC is our first clinical site from a timeline perspective and has a history of high-quality clinical research and exceptional patient care, and it represents an ideal setting for a rigorous evaluation of our cell therapy candidate,” stated Pietro Bersani, Kiromic Chief Executive Officer. “We are also actively engaging and making continued progress with other prestigious clinical trial sites to expand the reach and the impact of this study across a total of up to four sites. We intend to provide updates on the progress of the Deltacel-01 clinical study, including subsequent site activations, as the trial advances.”

NSCLC is the most prevalent type of lung cancer, representing about 80% to 85% of lung cancer cases. Lung cancer is by far the leading cause of cancer death in the U.S., accounting for about 1 in 5 of all cancer deaths.

### About Kiromic BioPharma

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit [www.kiromic.com](http://www.kiromic.com) and connect with us on Twitter and LinkedIn.

### Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Kiromic makes such forward-looking statements pursuant to the safe harbor provisions of the United States Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as: “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding: Kiromic’s ability to achieve its objectives and Kiromic’s financing strategy and availability of funds. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, and as detailed from time to time in our other SEC filings. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Such forward-looking statements relate only to events as of the date of this press release. We undertake no obligation to update any forward-looking statements except to the extent required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231023260123/en/): <https://www.businesswire.com/news/home/20231023260123/en/>

**Kiromic BioPharma**

Linda Phelan Dyson, MPH  
Global Head, Corporate Communications  
[ldyson@kiromic.com](mailto:ldyson@kiromic.com)  
281-468-7683

**LHA Investor Relations**

Tirth T. Patel  
[tpatel@lhai.com](mailto:tpatel@lhai.com)  
212-201-6614

Source: Kiromic BioPharma, Inc.